 |
| D-1 and PD-L1 inhibitor market |
The PD-1 and PD-L1 inhibitor market is estimated to be valued at US$ 39.83 Bn in 2023 and is expected to exhibit a CAGR of 14.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
PD-1 and PD-L1 inhibitors are immune checkpoint inhibitors used in cancer
immunotherapy. They work by blocking proteins called PD-1 and PD-L1 that help
tumors hide from the immune system. By blocking these proteins, they help
stimulate the immune system to attack cancer cells. They are used to treat
various cancers including melanoma, lung cancer, kidney cancer, head and neck
cancer etc.
Market Dynamics:
The growth of the PD-1 and PD-L1 inhibitor market is driven by rising
prevalence of cancer worldwide and increasing adoption of immunotherapy for
cancer treatment. According to WHO, cancer burden rose to 19.3 million cases
and 10 million cancer deaths in 2020. The two major types of cancer, lung
cancer and breast cancer, accounted for 11.4% of all new cancer cases. Rise in
geriatric population who are more prone to developing cancer is also fueling
the market growth. Furthermore, increasing approval of PD-1 and PD-L1
inhibitors for various cancer types and ongoing clinical trials evaluating the
use of these inhibitors in new cancer indications are creating new market
opportunities. However, high cost of immunotherapy drugs is expected to hinder
the market growth.
SWOT Analysis
Strength: PD-1 and PD-L1 inhibitors have shown promising results in clinical
trials for various cancer types. They exhibit fewer side effects compared to
standard chemotherapy. The drugs have received favorable reimbursement policies
from governments and insurance providers globally.
Weakness: High development costs associated with novel immunotherapies make
these drugs expensive for patients. Toxicities associated with PD-1 and PD-L1
inhibitors require continued monitoring during and after treatment.
Opportunity: Increasing incidence of cancer globally presents a massive patient
pool for PD-1 and PD-L1 inhibitors. Expanding indication approvals to new
cancer types will further boost the market. Combination therapies hold
potential to enhance clinical efficacy.
Threats: Patent expirations of blockbuster drugs may lead to launch of
biosimilars, posing pricing pressure. Failure to demonstrate benefits in
clinical studies can negatively impact future prospects. Stringent regulatory
norms across regions add to developmental challenges.
Key Takeaways
The global PD-1
And PD-L1 Inhibitor Market Share is expected to witness high growth,
exhibiting CAGR of 14% over the
forecast period, due to increasing incidence of cancer globally. Approval for new
cancer indications and launch of combination therapies will further augment
market revenues.
Regional analysis - North America currently dominates the global market and is
expected to continue its dominance over the forecast period. This can be attributed
to growing cancer burden, favorable reimbursement policies, and robust research
infrastructure in the region. However, Asia Pacific is anticipated to witness
the highest growth rate owing to rising healthcare expenditure, large patient
pool and emergence of local key players.
Key players operating in the PD-1 and PD-L1 Inhibitor market are Pfizer Inc.,
Novartis AG, AstraZeneca PLC, Gilead Sciences Inc., Amgen Inc., Sanofi AG,
Hoffmann-La Roche AG, Merck & Co., Bristol-Myers Squibb Company, and
Regeneron Pharmaceuticals Inc. These players are focused on expanding their
product pipelines through collaborative agreements and clinical trials to
consolidate market presence.
Read More,
https://www.trendingwebwire.com/pd-1-and-pd-l1-inhibitor-market-trends-size-and-share-analysis/
0 Comments